Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07171112 · ClinicalTrials.gov registry record · Phase 2
Smoking Cessation Trial in Recurrent Acute Pancreatitis and Chronic Pancreatitis
A Phase 2 study of Smoking (Tobacco) Addiction and Recurrent Acute Pancreatitis, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT07171112: Recruiting Phase 2 study of Smoking (Tobacco) Addiction and Recurrent Acute Pancreatitis, sponsored by Mayo Clinic.
NCT07171112 is a Phase 2 study of Smoking (Tobacco) Addiction and Recurrent Acute Pancreatitis that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 45 participants, below the 387-participant average among 6 other Smoking (Tobacco) Addiction trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07171112, a Phase 2 study of Smoking (Tobacco) Addiction and Recurrent Acute Pancreatitis, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to assess the effectiveness of two treatment strategies for smoking cessation in patients with acute recurrent pancreatitis or chronic pancreatitis who smoke cigarettes. All participants will receive varenicline, a commonly used medication that helps people stop smoking, at its standard dose. For those who are unable to stop smoking after 6 weeks of treatment, they will be randomly selected to either 1) increase their dose of varenicline, 2) combine varenicline with bupropion (another medication that helps with smoking cessation) or continue on the standard dose of varenicline. At the end of 12 weeks of treatment, participants will be asked if they have stopped smoking with confirmation done by measuring carbon monoxide levels in their breath.
Conditions Studied
Interventions
- DRUG Standard Varenicline Dosing (1 mg BID)
- DRUG Bupropion 150 mg twice daily
- DRUG Increased Varenicline Dosing (1mg TID)
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-11-06 |
| Est. Completion | 2028-10-01 |
| Phase | Phase 2 |
What NCT07171112 shows while recruiting
NCT07171112 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 387-participant average among 6 other Smoking (Tobacco) Addiction trials with a reported enrollment target (88% lower).
The record links to 4 conditions, with Smoking (Tobacco) Addiction appearing as the primary indexed condition, and to 3 interventions - of which Standard Varenicline Dosing (1 mg BID) is the first listed.
NCT07171112 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT07171112 about?
NCT07171112 is a clinical study titled "Smoking Cessation Trial in Recurrent Acute Pancreatitis and Chronic Pancreatitis". The purpose of this research is to assess the effectiveness of two treatment strategies for smoking cessation in patients with acute recurrent pancreatitis or chronic pancreatitis who smoke cigarettes. All participants will receive varenicline, a commonly used medication that helps people stop smoki...
What is the current status of trial NCT07171112?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2025-11-06. Estimated completion is 2028-10-01.
What conditions does trial NCT07171112 study?
This clinical trial studies the following conditions: Smoking (Tobacco) Addiction, Recurrent Acute Pancreatitis, Pancreatitis, Chronic, Pancreatitis, Acute.
What interventions are being tested in trial NCT07171112?
The interventions under investigation include: Standard Varenicline Dosing (1 mg BID) (DRUG), Bupropion 150 mg twice daily (DRUG), Increased Varenicline Dosing (1mg TID) (DRUG).
Who is sponsoring clinical trial NCT07171112?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07171112 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking (Tobacco) Addiction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Oklahoma Study of Native American Pain Risk IV: Smoking Cessation and Pain
RECRUITING · NA
-
ACT Lung Health Intervention: Phase Two
RECRUITING · NA
-
A Study Evaluating the Use of an Indoor Air Quality Monitor to Promote a Smoke-free Home
RECRUITING · NA
-
Addiction Potential of Very Low Nicotine Filtered Little Cigars
RECRUITING · Phase 4
-
Helping Poor Smokers Quit
COMPLETED · NA
-
Addiction and Behavior Related to Menthol Cigarette Substitutes
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI